{
    "clinical_study": {
        "@rank": "104340", 
        "arm_group": [
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "patient will receive placebo once daily, 2 puffs in the morning"
            }, 
            {
                "arm_group_label": "tiotropium + olodaterol high dose", 
                "arm_group_type": "Experimental", 
                "description": "patient will receive tiotropium 5 mcg + olodaterol 5 mcg in fixed dose combination once daily, 2 puffs in the morning"
            }, 
            {
                "arm_group_label": "tiotropium", 
                "arm_group_type": "Active Comparator", 
                "description": "patient will receive tiotropium 5 mcg once daily, 2 puffs in the morning"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objectives of the study are to explore the effect of treatment with orally\n      inhaled tiotropium + olodaterol fixed dose combination  with and without exercise training,\n      and tiotropium comparing to placebo, on top of behavioural modification in improving\n      exercise capacity in patients with COPD"
        }, 
        "brief_title": "To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Pulmonary Disease, Chronic Obstructive", 
        "condition_browse": {
            "mesh_term": [
                "Chronic Disease", 
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  All patients must sign an informed consent consistent with International Conference\n             on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for\n             Human Use (ICH) - Good Clinical Practice (GCP) guidelines prior to participation in\n             the trial, which includes medication washout and restrictions.\n\n          -  All patients must have a diagnosis of chronic obstructive pulmonary disease and must\n             meet the following spirometric criteria: Patients must have relatively stable airway\n             obstruction with a post-bronchodilator forced expiratory volume in one second >=30%\n             and <80% of predicted normal; Global Initiative for Chronic Obstructive Lung Disease\n             grade II - III, and a post-bronchodilator Tiffeneau index <70% at Visit 1.\n\n          -  Male or female patients, aged >=40 years and <=75 years.\n\n          -  Patients must be current or ex-smokers with a smoking history of more than 10 pack\n             years. Patients who have never smoked cigarettes must be excluded.\n\n        Exclusion criteria:\n\n          -  Patients with a significant disease other than chronic obstructive pulmonary disease.\n\n          -  Patients with clinically relevant abnormal baseline haematology, blood chemistry, or\n             urinalysis.\n\n          -  Patients with a history of asthma.\n\n          -  A diagnosis of thyrotoxicosis.\n\n          -  A diagnosis of paroxysmal tachycardia (>100 beats per minute).\n\n          -  A history of myocardial infarction within 1 year of screening visit.\n\n          -  Unstable or life-threatening cardiac arrhythmia.\n\n          -  Hospitalized for heart failure within the past year.\n\n          -  Known active tuberculosis.\n\n          -  A malignancy for which patient has undergone resection, radiation therapy or\n             chemotherapy within last five years.\n\n          -  A history of life-threatening pulmonary obstruction and patients with chronic\n             respiratory failure.\n\n          -  A history of cystic fibrosis.\n\n          -  Clinically evident bronchiectasis.\n\n          -  A history of significant alcohol or drug abuse.\n\n          -  Any contraindications for exercise testing.\n\n          -  Patients who have undergone thoracotomy with pulmonary resection.\n\n          -  Patients being treated with any oral \u00df-adrenergics.\n\n          -  Patients being treated with oral corticosteroid medication at unstable doses (i.e.,\n             less than six weeks on a stable dose) or at doses in excess of the equivalent of 10\n             mg of prednisone per day or 20 mg every other day.\n\n          -  Patients who regularly use daytime oxygen therapy for more than one hour per day and\n             in the investigators opinion will be unable to abstain from the use of oxygen therapy\n             during clinic visits.\n\n          -  Patients who have completed a pulmonary rehabilitation program in the six weeks prior\n             to the screening visit or patients who are currently in a pulmonary rehabilitation\n             program.\n\n          -  Patients who have a limitation of exercise performance as a result of factors other\n             than fatigue or exertional dyspnoea, such as arthritis in the leg, angina pectoris or\n             claudication or morbid obesity.\n\n          -  Patients who have taken an investigational drug within one month or six half lives\n             (whichever is greater) prior to screening visit.\n\n          -  Patients with known hypersensitivity to \u00df-adrenergics drugs, anticholinergic drugs,\n             benzalkonium chloride, disodium edentat, or any other component of the Respimat\u00ae\n             inhalation solution delivery system.\n\n          -  Pregnant or nursing women.\n\n          -  Women of childbearing potential not using highly effective methods of birth control.\n\n          -  Patients who have previously been randomized in this study or are currently\n             participating in another study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02085161", 
            "org_study_id": "1237.16", 
            "secondary_id": "2013-002671-18"
        }, 
        "intervention": [
            {
                "arm_group_label": "placebo", 
                "description": "comparator", 
                "intervention_name": "placebo to tiotropium + olodaterol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "tiotropium", 
                "description": "tiotropium 5 mcg once daily", 
                "intervention_name": "tiotropium", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "tiotropium + olodaterol high dose", 
                "description": "olodaterol 5 mcg once daily fixed dose combination", 
                "intervention_name": "olodaterol", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "tiotropium + olodaterol high dose", 
                "description": "tiotropium 5 mcg once daily fixed dose combination", 
                "intervention_name": "tiotropium", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tiotropium"
        }, 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Daw Park", 
                        "country": "Australia", 
                        "state": "South Australia"
                    }, 
                    "name": "1237.16.61601 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toorak Gardens", 
                        "country": "Australia", 
                        "state": "South Australia"
                    }, 
                    "name": "1237.16.61602 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hasselt", 
                        "country": "Belgium"
                    }, 
                    "name": "1237.16.32602 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium"
                    }, 
                    "name": "1237.16.32601 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec"
                    }, 
                    "name": "1237.16.11601 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec"
                    }, 
                    "name": "1237.16.11604 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ste-Foy", 
                        "country": "Canada", 
                        "state": "Quebec"
                    }, 
                    "name": "1237.16.11602 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saskatoon", 
                        "country": "Canada", 
                        "state": "Saskatchewan"
                    }, 
                    "name": "1237.16.11603 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kolding", 
                        "country": "Denmark"
                    }, 
                    "name": "1237.16.45003 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "K\u00f8benhavn NV", 
                        "country": "Denmark"
                    }, 
                    "name": "1237.16.45002 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Odense", 
                        "country": "Denmark"
                    }, 
                    "name": "1237.16.45001 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greenlane East Auckland NZ", 
                        "country": "New Zealand"
                    }, 
                    "name": "1237.16.64601 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Coimbra", 
                        "country": "Portugal"
                    }, 
                    "name": "1237.16.35601 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lisboa", 
                        "country": "Portugal"
                    }, 
                    "name": "1237.16.35604 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Matosinhos", 
                        "country": "Portugal"
                    }, 
                    "name": "1237.16.35602 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Porto", 
                        "country": "Portugal"
                    }, 
                    "name": "1237.16.35603 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leicester", 
                        "country": "United Kingdom"
                    }, 
                    "name": "1237.16.44602 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Norwich", 
                        "country": "United Kingdom"
                    }, 
                    "name": "1237.16.44601 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sheffield", 
                        "country": "United Kingdom"
                    }, 
                    "name": "1237.16.44603 Boehringer Ingelheim Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Australia", 
                "Belgium", 
                "Canada", 
                "Denmark", 
                "New Zealand", 
                "Portugal", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "An Exploratory, 12 Week, Randomised, Partially Double-blinded, Placebo-controlled Parallel Group Trial to Explore the Effects of Once Daily Treatments of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination or Tiotropium (Both Delivered by Respimat\u00ae Inhaler), Supervised Exercise Training and Behavior Modification on Exercise Capacity and Physical Activity in Patients With Chronic Obstructive Pulmonary Disease (COPD)", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Australia: Therapeutic Goods Administration", 
                "Austria: Medicines and Medical Devices Agency", 
                "Belgium: Federal Agency for Medicinal and Health Products", 
                "Canada: Health Canada", 
                "Denmark: The Danish Health and Medicines Authority", 
                "Germany: Federal Institute for Drugs and Medical Devices", 
                "Italy: Ministry of Health", 
                "New Zealand: Medsafe", 
                "Poland: Registration Medicinal Product Medical Device Biocidal Product", 
                "Portugal: National Pharmacy and Medicines Institute", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration"
            ]
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Endurance time [sec] during Endurance Shuttle Walk Test  to symptom limitation at walking speed corresponding to 85% of predicted maximum  oxygen consumption after 8 weeks of treatment", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "removed_countries": {
            "country": "Germany"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02085161"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Resting inspiratory capacity measured at 1.5 hours post dose after 8 weeks of treatment", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Average daily walking time measured by the activity monitor in the week prior to 12 weeks of treatment", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Average daily walking intensity measured by the activity monitor in the week prior to 12 weeks of treatment", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Functional Performance Inventory-Short Form score at Week 12", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Endurance time [sec] during Endurance Shuttle Walk Test  to symptom limitation at walking speed corresponding to 85% of predicted maximum  oxygen consumption after 12 weeks of treatment", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "One hour post-dose forced expiratory volume in one second after 8 weeks of treatment", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "One hour post-dose forced vital capacity after 8 weeks of treatment", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}